title: Changes in parameters of the coagulation-fibrinolysis system and platelet function after OKY-046 administration to patients with ruptured aneurysm of the cerebral artery.
abstract: The influence of the TXA2-synthetase inhibitor OKY-046 (Xanbon) on haematological findings for the coagulation-fibrinolysis system and platelet aggregation was investigated in patients with subarachnoid bleeding during or after the administration. Changes in alpha 2-PI activity and the levels of fibrinogen, t-PA and PAI antigen were observed. Especially, PAI activity and PAI antigen were found to be significantly increased as compared with levels before the administration. On the other hand, the platelet aggregation induced by various agents and the activity of AT-III were not greatly altered after the administration of OKY-046.
authors.affiliation: Department of Physiology, School of Medicine, University of Ryukyus, Okinawa, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kosugi
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.forename: S
authors.initials: S
authors.lastname: Saitoh
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: T
authors.initials: T
authors.lastname: Shimoji
authors.forename: S
authors.initials: S
authors.lastname: Minei
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001777:Blood Coagulation / Q000187:drug effects*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D003094:Collagen / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D002532:Intracranial Aneurysm / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008689:Methacrylates / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D015849:Plasminogen Inactivators / Q000378:metabolism; D010972:Platelet Activating Factor / Q000378:metabolism; D012422:Rupture, Spontaneous / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
chemical_list: D008689:Methacrylates; D015849:Plasminogen Inactivators; D010972:Platelet Activating Factor; D000244:Adenosine Diphosphate; D005340:Fibrinogen; D003094:Collagen; D010959:Tissue Plasminogen Activator; D013930:Thromboxane-A Synthase; C034364:ozagrel